Immunic/$IMUX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunic
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Ticker
$IMUX
Sector
Primary listing
Employees
95
Headquarters
Website
Immunic Metrics
BasicAdvanced
$193m
-
-$7.66
1.39
-
Price and volume
Market cap
$193m
Beta
1.39
52-week high
$15.77
52-week low
$8.50
Average daily volume
248k
Financial strength
Current ratio
4.92
Quick ratio
4.874
Long term debt to equity
0.097
Total debt to equity
0.278
Profitability
EBITDA (TTM)
-109.48
Management effectiveness
Return on assets (TTM)
-65.18%
Return on equity (TTM)
-142.91%
Valuation
Price to book
1.28
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
-2.375
Free cash flow yield (TTM)
-42.11%
Free cash flow per share (TTM)
-5.979
Growth
Earnings per share change (TTM)
-19.64%
3-year earnings per share growth (CAGR)
-39.73%
Immunic News
AllArticlesVideos
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
Proactive Investors·3 weeks ago
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
Proactive Investors·3 weeks ago
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
Proactive Investors·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs